title: Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease.
abstract: OBJECTIVE
  Although the use of drugs which damage stem cells is common in patients with Hodgkin's disease (HD), factors affecting peripheral blood progenitor cell (PBPC) mobilization have not been clearly established in this group of patients. The aim of this study was to identify factors associated with poor PBPC mobilization in patients with HD.
  
  
  METHODS
  In order to address this issue we have evaluated in 54 patients with HD mobilized with G-CSF alone the following factors: sex, age, histologic subtype, B symptoms at diagnosis, status of remission, previous chemotherapy and radiotherapy, interval from diagnosis and last chemotherapy cycle to harvest, and dose of G-CSF. Univariate analysis was performed using Student's t-test, Pearson's correlation and Spearman's correlation. A stepwise regression model was used to determine which of the variables was the most predictive of PBPC mobilization.
  
  
  RESULTS
  In univariate analysis poorer PBPC mobilization was observed in patients who had previously received at least two courses of mini-BEAM (p=0.006), a high number of different chemotherapy regimens (p=0.002), a chemotherapy score >30 (p=0.02) and more than 9 months of alkylating agents (p=0.07). We did not find radiotherapy to be a significant factor affecting progenitor cell yield (p=0.59). In the stepwise regression model, only the previous administration of two or more mini-BEAM cycles predicted a poor PBPC yield (p=0.006).
  
  
  CONCLUSIONS
  Previous chemotherapy, principally exposure to a mini-BEAM regimen, seems to be the principal factor affecting collection of PBPC in patients with HD mobilized with G-CSF alone. Since mini-BEAM is an effective salvage regimen in relapsed or refractory HD, collection of PBPC should be planned when there has been no or only minimal exposure to a mini-BEAM regimen.
authors: Servicio de Hematología, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain. canalesmiguel@hotmail.com
authors: M A
authors: MA
authors: Canales
authors: M C
authors: MC
authors: Fernández-Jiménez
authors: A
authors: A
authors: Martín
authors: R
authors: R
authors: Arrieta
authors: M D
authors: MD
authors: Caballero
authors: J
authors: J
authors: Díez
authors: E
authors: E
authors: Quevedo
authors: J
authors: J
authors: García-Bustos
authors: J F
authors: JF
authors: San Miguel
authors: F
authors: F
authors: Hernández-Navarro
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000592:standards*; D006689:Hodgkin Disease / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007937:Leukapheresis / Q000592:standards; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents